BioPharmSignal logoBioPharmSignal

Biotech News

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Cabaletta Bio (CABA)Cabaletta BioCompany update

CABA (CABA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is caba.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

CABACabaletta Bio2026-08-13 11:30 EST

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

CABACabaletta Bio2026-09-01 12:00 EST

Cabaletta Bio to Participate in Upcoming Investor Conferences

CUECue Biopharma Inc2026-07-13 12:30 EST

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development

HCMHUTCHMED2026-06-12 00:00 EST

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

INMBINmune Bio2026-09-14 11:00 EST

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

BMYBMYBristol-Myers Squibb Company2026-08-29 15:00 EST

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

INMBINmune Bio2026-07-30 11:00 EST

INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform

IMVTImmunovant2026-08-06 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

HCWBHCW Biologics2026-08-14 19:15 EST

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results

ZURAZura Bio2026-08-11 11:30 EST

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

View all latest news

Cabaletta Bio

Autoimmune Cell Therapy Company Cabaletta Bio develops engineered T-cell therapies intended to produce deep and durable responses in autoimmune disease. Rese-cel Rese-cel is a fully human CD19-directed CAR T-cell therapy being studied across myositis, systemic lupus erythematosus, systemic sclerosis, and pemphigus vulgaris. CARTA...

Recent company news

CABACabaletta Bio2026-09-01 12:00 EST

Cabaletta Bio to Participate in Upcoming Investor Conferences

CABACabaletta Bio2026-08-13 11:30 EST

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

CABACabaletta Bio2026-06-03 11:00 EST

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

CABACabaletta Bio2026-05-14 11:05 EST

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update

CABACabaletta Bio2026-05-14 11:00 EST

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

Stock data

Close
2.58 USD
Market cap
600.04M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States